For Immediate Release
Chicago, IL – April 23, 2019 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:Wells Fargo (WFC - Free Report) , UnitedHealth (UNH - Free Report) , Merck (MRK - Free Report) , Schwab (SCHW - Free Report) and Raytheon (RTN - Free Report) .
Here are highlights from last Thursday’s Analyst Blog:
Top Analyst Reports for Wells Fargo, UnitedHealth and Merck
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Wells Fargo, UnitedHealth and Merck. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
You can see all of today’s research reports here >>>
Wells Fargo’s shares have underperformed the Zacks Major Regional Banks industry in the past six months, (-10.3% vs. -0.8%). Its earnings surprise history is decent, having beaten expectations in two of the trailing four quarters.
The first-quarter 2019 results reflect lower expenses and elevated net interest income, partly offset by decline in loans and deposits. However, fee income and provisions disappointed. The Zacks analyst likes Wells Fargo’s ongoing investment in its businesses to enhance compliance and risk management capability, build a better bank and strengthen core infrastructure.
However, the financial major was slapped with several sanctions, including a cap on its assets by the Federal Reserve which will continue, as recently the U.S. Consumer Financial Protection Bureau director expressed her dissatisfaction with the bank’s progress toward fixing its risk management issues, following the company’s involvement in several legal issues. Falling mortgage banking income is another concern.
Shares of Buy-ranked UnitedHealth have lost -11.3% year to date, underperforming the Zacks Medical Insurance industry, which has declined -5.6% over the same period. UnitedHealth Group’s first-quarter earnings surpassed expectations by 3.6% and were up 22.7% year over year. Higher revenues at both segments — UnitedHealthcare and Optum — plus membership growth led to this outperformance.
The Zacks analyst likes the company's solid balance sheet, strong operating performance, favorable business profile and disciplined enterprise risk management. The company also benefits from the services, technology and innovations offered by its Optum segment. However, slowdown of growth in international operations, underperformance in Medicaid business, and increase in leverage and interest burden are major headwinds.
Buy-ranked Merck’s shares have increased +1.5% year to date, outperforming the Zacks Large Cap Pharmaceuticals industry’s gain of +0.3% during the same period. The Zacks analyst thinks Merck’s new products like Keytruda, Lynparza, and Bridion are contributing meaningfully to the top line.
Keytruda sales are gaining momentum with approval for additional indications, especially in the first-line lung cancer setting. Keytruda has strong growth prospects based on increased utilization, recent approvals for new indications and potential additional approvals worldwide. Animal health and vaccine products are also performing strongly and remain core growth drivers for Merck.
However, generic competition for several drugs and pricing pressure will continue to be overhangs on the top line. Rising competitive pressure on the diabetes franchise and products like Isentress (HIV), Zepatier (HCV) and Zostavax (vaccine) remains a concern. Estimates have gone up slightly ahead of Q1 results. Merck has a positive record of earnings surprises in the recent quarters.
Other noteworthy reports we are featuring today include Schwab and Raytheon.
Radical New Technology Creates $12.3 Trillion Opportunity
Imagine buying Microsoft stock in the early days of personal computers… or Motorola after it released the world’s first cell phone. These technologies changed our lives and created massive profits for investors.
Today, we’re on the brink of the next quantum leap in technology. 7 innovative companies are leading this “4th Industrial Revolution” - and early investors stand to earn the biggest profits.
See the 7 breakthrough stocks now>>
Zacks Investment Research
800-767-3771 ext. 9339
Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.